Pfizer and BioNTech to potentially supply EU with 200 million doses of mRNA-based vaccine candidate against SARS-CoV-2

Exploratory talks have concluded with European Commission for proposed supply of investigational BNT162 mRNA-based vaccine candidate, with option for further 100 million doses. Deliveries would be starting by end of 2020, subject to clinical success and regulatory authorisation.


Biospace Inc.